Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYDRO-SERP "25" vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrochlorothiazide inhibits the Na+/Cl- symporter in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and promoting diuresis. Reserpine depletes catecholamines in postganglionic sympathetic nerve endings by inhibiting the vesicular monoamine transporter, leading to reduced sympathetic outflow and vasodilation.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Hypertension
Hypertension
Hydrochlorothiazide 25 mg orally once daily in the morning. Maximum 100 mg/day.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Reserpine: terminal elimination half-life 33-45 hours (range 30-60 hours), with clinical context of prolonged autonomic effects lasting days; hydrochlorothiazide: terminal half-life 6-15 hours (mean 10 hours).
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Hydrochlorothiazide is not extensively metabolized; reserpine is extensively metabolized in the liver via CYP450 enzymes.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Renal (approximately 30-50% as unchanged drug and metabolites), biliary/fecal (approximately 50-70% as metabolites, with enterohepatic recirculation noted for reserpine component).
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Reserpine: 95-98% bound to plasma proteins; hydrochlorothiazide: 60-70% bound to albumin.
~90%, primarily to albumin
Reserpine: Vd approximately 0.5-0.7 L/kg, indicating extensive tissue distribution and high lipophilicity; hydrochlorothiazide: Vd 0.2-0.4 L/kg, primarily confined to extracellular fluid.
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Reserpine: oral bioavailability approximately 50% due to first-pass metabolism; hydrochlorothiazide: oral bioavailability 65-75%.
Oral: 50–60% (extensive first-pass metabolism)
GFR 30-50 m L/min: 25 mg once daily. GFR 15-29 m L/min: not recommended. GFR <15 m L/min: contraindicated.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
Child-Pugh Class A or B: no adjustment. Child-Pugh Class C: use with caution, consider starting at 12.5 mg daily.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Weight-based: 1-2 mg/kg/day orally divided every 12-24 hours, maximum 100 mg/day.
Not recommended for pediatric use; safety in children under 12 years not established.
Start at 12.5 mg daily; monitor electrolytes and renal function; may increase to 25 mg daily if needed.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
None
None
May cause electrolyte imbalance (hypokalemia, hyponatremia),May exacerbate systemic lupus erythematosus,Reserpine may cause mental depression, peptic ulcer, and nasal congestion,Photosensitivity,Orthostatic hypotension with reserpine
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Anuria,Sulfonamide allergy (hydrochlorothiazide is a sulfonamide),Known hypersensitivity to hydrochlorothiazide or reserpine,Active peptic ulcer (due to reserpine),Electroconvulsive therapy (within 7 days, due to reserpine)
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Avoid high-sodium foods to enhance antihypertensive effect. Limit alcohol intake as it may potentiate hypotension. Grapefruit juice may alter drug metabolism; avoid excessive consumption. Maintain adequate potassium intake (bananas, oranges) unless advised otherwise by your doctor.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
FDA Pregnancy Category D. Use of reserpine in the first trimester is associated with an increased risk of congenital malformations, including neural tube defects and cardiovascular anomalies. In the second and third trimesters, exposure may cause fetal bradycardia, hypothermia, and respiratory depression due to depletion of catecholamines. Chronic use may lead to fetal growth restriction.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
Reserpine is excreted into breast milk with an M/P ratio of 0.5. Due to the potential for serious adverse reactions in nursing infants, including gastrointestinal disturbances, nasal congestion, and lethargy, breastfeeding is contraindicated during reserpine therapy.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
No pharmacokinetic studies are available to guide dosing adjustments during pregnancy; however, due to increased plasma volume and renal clearance, the effective dose may need to be increased, but this must be balanced against fetal risks. The lowest effective dose should be used and the drug should be discontinued if possible, especially during the third trimester to avoid neonatal effects.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
Hydro-Serp '25' contains hydrochlorothiazide 25 mg and reserpine 0.125 mg. Monitor serum potassium and magnesium; hypokalemia increases digitalis toxicity risk. Reserpine may cause mental depression; use with caution in patients with history of depression. Taper reserpine before surgery to avoid hypertensive rebound. Avoid concurrent use with MAOIs.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Take exactly as prescribed; do not discontinue abruptly.,This medication may make you dizzy or drowsy; avoid driving until you know how it affects you.,Rise slowly from sitting or lying to prevent falls from low blood pressure.,Report any mood changes, depression, or vivid dreams to your doctor.,Use sunscreen and protective clothing; this drug increases sun sensitivity.,Do not use potassium supplements or salt substitutes without asking your doctor.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HYDRO-SERP "25" vs ALDORIL 15, answered by our medical review team.
HYDRO-SERP "25" is a Antihypertensive Combination that works by Hydrochlorothiazide inhibits the Na+/Cl- symporter in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and promoting diuresis. Reserpine depletes catecholamines in postganglionic sympathetic nerve endings by inhibiting the vesicular monoamine transporter, leading to reduced sympathetic outflow and vasodilation.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HYDRO-SERP "25" and ALDORIL 15 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HYDRO-SERP "25" is: Hydrochlorothiazide 25 mg orally once daily in the morning. Maximum 100 mg/day.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HYDRO-SERP "25" and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HYDRO-SERP "25" is classified as Category C. FDA Pregnancy Category D. Use of reserpine in the first trimester is associated with an increased risk of congenital malformations, including neural tube defects and cardiovascular. ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.